Publications

Mihalchik AL, Choksi NY, Roe AL, Wisser M, Whitaker K, Seibert D, Deore M, Pavlick L, Wikoff DS. 2024. Safety evaluation of 8 drug degradants present in over-the-counter cough and cold medications. Regul Toxicol Pharmacol 149(May):105621; doi: 10.1016/j.yrtph.2024.105621. PMID: 38608922.

Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V,… Suh M, Reichert H, Mezzi K, Fryzek J, et al. 2024. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur J Cancer 202:113975; doi: 10.1016/j.ejca.2024.113975. PMID:  38442645.

Nelms MD, Antonijevic T, Ring C, Harris DL, Bever RJ, Lynn SG, … Borghoff S, et al. 2024. Chemistry domain of applicability evaluation against existing estrogen receptor high-throughput assay-based activity models. Front Toxicol 6(April 17):1346767; https://doi.org/10.3389/ftox.2024.1346767. PMID: 38694816.

Mittal L, Perry CS, Blanchette AD, Proctor DM. 2024. Probabilistic risk assessment of residential exposure to electric arc furnace steel slag using Bayesian model of relative bioavailability and PBPK modeling of manganese. Risk Anal 44(9):2169-2186. doi: 10.1111/risa.14309. PMID: 38622492.

Suh M, Movva N, Jiang X, Reichert H, Pastula ST, Sacks NC, Frankenfeld C, Fryzek JP, Simões AF. 2024. Healthcare utilization among infants covered by Medicaid and newly diagnosed with respiratory syncytial virus. Open Forum Infect Dis 11(4)::ofae174; doi: 10.1093/ofid/ofae174. PMID: 38595954.

Heintz MM, Klaren WD, East AW, Haws LC, McGreal SR, Campbell RR, Thompson CM. 2024. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes. Toxicol Sci 200(1):165–182; doi: 10.1093/toxsci/kfae044.  PMID: 38574381.

Heintz MM, Klaren WD, East AW, Haws LC, McGreal SR, Campbell RR, Thompson CM. 2024. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mouse hepatocytes. Toxicol Sci 200(1):183–198; doi: 10.1093/toxsci/kfae045. PMID: 38574385.

Bever RJ, Edwards SW, Antonijevic T, Nelms MD, Ring C, Harris D, Lynn SG, Williams D, Chappell G, Boyles R, Borghoff S, Markey KJ. 2024. Optimizing androgen receptor prioritization using high-throughput assay-based activity models. Front Toxicol 6(March 11):1347364; doi: 10.3389/ftox.2024.1347364. PMID: 38529103.

Racz L, Gauthier A, Bare J, Heintz M, Feifarek D, Kennedy S, Panko J. 2024. Assessment of perfluorocarboxylic acids in fluorinated high-density polyethylene containers and estimation of potential non-cancer risks associated with anticipated use scenarios. Regul Toxicol Pharmacol 147:105560; doi: 10.1016/j.yrtph.2024.105560.

Fitch S, Blanchette A, Haws LC, Franke K, Ring C, DeVito M,… Wikoff DS. 2024. Systematic update to the mammalian relative potency estimate database and development of best estimate toxic equivalency factors for dioxin-like compounds. Regul Toxicol Pharmacol 147(Feb):105571; doi: 10.1016/j.yrtph.2024.105571.